प्राथमिक स्रोत रिकॉर्ड
निर्णायकअन्य
Lilly, TRD में BPL-003 के लिए AtaiBeckley का अधिग्रहण करेगी
Lilly signed a definitive agreement to acquire AtaiBeckley, gaining BPL-003 (mebufotenin benzoate nasal spray) and VLS-01 (DMT buccal film) for treatment-resistant depression. The deal includes $2.8 billion upfront equity value plus up to $1.0 billion in CVR milestones tied to Phase 3 initiation and U.S. approvals. BPL-003 has Breakthrough Therapy Designation and has already initiated Phase 3 activities.
मुख्य तथ्य
- फाइल किया गया
- 16 जुल॰ 2026, 11:27 am
- घटना
- अन्य
- दिशा
- सकारात्मक
- कंपनी
ATAIAtaiBeckley- संपत्ति
- BPL-003
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- शेयर मूल्य
- $6.75 नकद + $2.50 सीवीआर तक
- सीवीआर क्षमता
- $1.0 बिलियन
- अग्रिम इक्विटी मूल्य
- $2.8 बिलियन
स्रोत का अंश
EX-99.1 4 ef20078103_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 July 16, 2026 For Release: Immediately Refer to: Jessica Bardoulas; jessica.bardoulas@lilly.com ; (Media) Michael Czapar; czapar_michael_c@lilly.com ; (Investors) Jason Awe, PhD; Jason.Awe@ataibeckley.com (Investors) Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 – Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company develop
इस संपत्ति पर और
उल्लेखनीय
6 जुल॰ 2026
10:00 am
ATAIAtaiBeckleyअटाईबेकले ने वीएलएस-01 फेज 2बी टीआरडी परीक्षण में डोजिंग पूरी की